{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T23:28:06Z","timestamp":1781047686765,"version":"3.54.1"},"reference-count":77,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cardiovascular Medicine"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.tcm.2023.01.003","type":"journal-article","created":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T20:38:54Z","timestamp":1674074334000},"page":"193-199","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Lp(a) - an overlooked risk factor"],"prefix":"10.1016","volume":"34","author":[{"given":"Luke J.","family":"Laffin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7231-6464","authenticated-orcid":false,"given":"Steven E.","family":"Nissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tcm.2023.01.003_bib0001","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1699-0463.1963.tb01808.x","article-title":"A New Serum Type System in Man\u2013the Lp System","volume":"59","author":"Berg","year":"1963","journal-title":"Acta Pathol Microbiol Scand"},{"issue":"5","key":"10.1016\/j.tcm.2023.01.003_bib0002","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1093\/cvr\/cvab100","article-title":"Treatment and prevention of lipoprotein(a)-mediated cardiovascular disease: the emerging potential of RNA interference therapeutics","volume":"118","author":"Swerdlow","year":"2022","journal-title":"Cardiovasc Res"},{"issue":"25","key":"10.1016\/j.tcm.2023.01.003_bib0003","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: a Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.tcm.2023.01.003_bib0004","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.tcm.2023.01.003_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacl.2022.08.007","article-title":"Use of Lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the National Lipid Association","author":"Wilson","year":"2022","journal-title":"J Clin Lipidol"},{"issue":"1","key":"10.1016\/j.tcm.2023.01.003_bib0006","first-page":"76","article-title":"Lipoprotein (a): structure, pathophysiology and clinical implications","volume":"103","author":"Maranhao","year":"2014","journal-title":"Arq Bras Cardiol"},{"issue":"7","key":"10.1016\/j.tcm.2023.01.003_bib0007","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S2213-8587(17)30088-8","article-title":"Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: a mendelian randomisation analysis","volume":"5","author":"Saleheen","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"10.1016\/j.tcm.2023.01.003_bib0008","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1161\/CIRCULATIONAHA.116.020838","article-title":"Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans","volume":"134","author":"van der Valk","year":"2016","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.tcm.2023.01.003_bib0009","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jacc.2021.10.044","article-title":"Association of Lipoprotein(a):with Atherosclerotic Plaque Progression","volume":"79","author":"Kaiser","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.tcm.2023.01.003_bib0010","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1194\/jlr.M040733","article-title":"Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a)","volume":"54","author":"Leibundgut","year":"2013","journal-title":"J Lipid Res"},{"issue":"12","key":"10.1016\/j.tcm.2023.01.003_bib0011","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1194\/jlr.P094763","article-title":"Potent reduction of plasma lipoprotein (a) with an antisense oligonucleotide in human subjects does not affect ex vivo fibrinolysis","volume":"60","author":"Boffa","year":"2019","journal-title":"J Lipid Res"},{"issue":"11","key":"10.1016\/j.tcm.2023.01.003_bib0012","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1194\/jlr.R071233","article-title":"Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology","volume":"57","author":"Nordestgaard","year":"2016","journal-title":"J Lipid Res"},{"issue":"16","key":"10.1016\/j.tcm.2023.01.003_bib0013","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1161\/CIRCULATIONAHA.109.913673","article-title":"Impact of thrombophilia on risk of arterial ischemic stroke or cerebral sinovenous thrombosis in neonates and children: a systematic review and meta-analysis of observational studies","volume":"121","author":"Kenet","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.tcm.2023.01.003_bib0014","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.atherosclerosis.2022.04.003","article-title":"Lipoprotein(a) beyond the kringle IV repeat polymorphism: the complexity of genetic variation in the LPA gene","volume":"349","author":"Coassin","year":"2022","journal-title":"Atherosclerosis"},{"issue":"9","key":"10.1016\/j.tcm.2023.01.003_bib0015","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1194\/jlr.M076232","article-title":"A genome-wide association meta-analysis on lipoprotein (a) concentrations adjusted for apolipoprotein (a) isoforms","volume":"58","author":"Mack","year":"2017","journal-title":"J Lipid Res"},{"issue":"Suppl 1","key":"10.1016\/j.tcm.2023.01.003_bib0016","first-page":"5","article-title":"Prediction of cardiovascular risk by Lp(a) concentrations or genetic variants within the LPA gene region","volume":"14","author":"Kronenberg","year":"2019","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.tcm.2023.01.003_bib0017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2020.03.003","article-title":"The dedicated \"Lp(a) clinic\": a concept whose time has arrived?","volume":"300","author":"Tsimikas","year":"2020","journal-title":"Atherosclerosis"},{"issue":"7","key":"10.1016\/j.tcm.2023.01.003_bib0018","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1004494","article-title":"Distribution and medical impact of loss-of-function variants in the Finnish founder population","volume":"10","author":"Lim","year":"2014","journal-title":"PLoS Genet"},{"issue":"1","key":"10.1016\/j.tcm.2023.01.003_bib0019","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12933-017-0520-z","article-title":"Lipoprotein(a) and incident type-2 diabetes: results from the prospective Bruneck study and a meta-analysis of published literature","volume":"16","author":"Paige","year":"2017","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.tcm.2023.01.003_bib0020","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1161\/ATVBAHA.120.315291","article-title":"Lp(a) (Lipoprotein[a]) Concentrations and Incident Atherosclerotic Cardiovascular Disease: new Insights From a Large National Biobank","volume":"41","author":"Patel","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"11","key":"10.1016\/j.tcm.2023.01.003_bib0021","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/aje\/kwp043","article-title":"Lipid changes during the menopause transition in relation to age and weight: the Study of Women's Health Across the Nation","volume":"169","author":"Derby","year":"2009","journal-title":"Am J Epidemiol"},{"issue":"11","key":"10.1016\/j.tcm.2023.01.003_bib0022","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1161\/ATVBAHA.116.308011","article-title":"Prevalence of Elevated Lp(a) Mass Levels and Patient Thresholds in 532 359 Patients in the United States","volume":"36","author":"Varvel","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"26","key":"10.1016\/j.tcm.2023.01.003_bib0023","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.tcm.2023.01.003_bib0024","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction","volume":"301","author":"Kamstrup","year":"2009","journal-title":"JAMA"},{"issue":"22","key":"10.1016\/j.tcm.2023.01.003_bib0025","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1161\/CIRCULATIONAHA.120.045826","article-title":"Lipoprotein(a) in Alzheimer, atherosclerotic, cerebrovascular, thrombotic, and valvular disease: mendelian randomization investigation","volume":"141","author":"Larsson","year":"2020","journal-title":"Circulation."},{"issue":"11","key":"10.1016\/j.tcm.2023.01.003_bib0026","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1093\/clinchem\/44.11.2301","article-title":"Lipoprotein(a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies","volume":"44","author":"Craig","year":"1998","journal-title":"Clin Chem"},{"issue":"10","key":"10.1016\/j.tcm.2023.01.003_bib0027","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1161\/01.CIR.102.10.1082","article-title":"Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies","volume":"102","author":"Danesh","year":"2000","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.tcm.2023.01.003_bib0028","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.atherosclerosis.2015.08.021","article-title":"Lipoprotein (a) as a risk factor for ischemic stroke: a meta-analysis","volume":"242","author":"Nave","year":"2015","journal-title":"Atherosclerosis"},{"issue":"27","key":"10.1016\/j.tcm.2023.01.003_bib0029","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1093\/eurheartj\/ehy334","article-title":"Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting","volume":"39","author":"Verbeek","year":"2018","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.tcm.2023.01.003_bib0030","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1161\/CIRCULATIONAHA.113.004406","article-title":"Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin)","volume":"129","author":"Khera","year":"2014","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.tcm.2023.01.003_bib0031","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jacc.2013.09.042","article-title":"Lipoprotein(a) for risk assessment in patients with established coronary artery disease","volume":"63","author":"O'Donoghue","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.tcm.2023.01.003_bib0032","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1161\/ATVBAHA.119.312951","article-title":"Lipoprotein(a)-Lowering by 50 mg\/dL (105 nmol\/L) May Be Needed to Reduce Cardiovascular Disease 20% in Secondary Prevention: a Population-Based Study","volume":"40","author":"Madsen","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"10.1016\/j.tcm.2023.01.003_bib0033","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.tcm.2023.01.003_bib0034","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.cjco.2019.03.004","article-title":"Lipoprotein(a), oxidized phospholipids, and aortic valve microcalcification assessed by 18f-sodium fluoride positron emission tomography and computed tomography","volume":"1","author":"Despres","year":"2019","journal-title":"CJC Open"},{"issue":"6","key":"10.1016\/j.tcm.2023.01.003_bib0035","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1001\/jamacardio.2020.0728","article-title":"An exploratory analysis of proprotein convertase subtilisin\/Kexin type 9 inhibition and aortic stenosis in the Fourier Trial","volume":"5","author":"Bergmark","year":"2020","journal-title":"JAMA Cardiol"},{"issue":"6","key":"10.1016\/j.tcm.2023.01.003_bib0036","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa1109034","article-title":"Genetic associations with valvular calcification and aortic stenosis","volume":"368","author":"Thanassoulis","year":"2013","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.tcm.2023.01.003_bib0037","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.jacc.2019.01.070","article-title":"Lipoprotein(a) and oxidized phospholipids promote valve calcification in patients with aortic stenosis","volume":"73","author":"Zheng","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.tcm.2023.01.003_bib0038","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/joim.12981","article-title":"Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities","volume":"287","author":"Vuorio","year":"2020","journal-title":"J Intern Med"},{"issue":"8","key":"10.1016\/j.tcm.2023.01.003_bib0039","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.cjca.2021.03.016","article-title":"2021 Canadian Cardiovascular Society Guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults","volume":"37","author":"Pearson","year":"2021","journal-title":"Can J Cardiol"},{"issue":"5","key":"10.1016\/j.tcm.2023.01.003_bib0040","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.jacl.2018.07.003","article-title":"Relationship of lipoprotein(a) molar concentrations and mass according to lipoprotein(a) thresholds and apolipoprotein(a) isoform size","volume":"12","author":"Tsimikas","year":"2018","journal-title":"J Clin Lipidol"},{"issue":"2","key":"10.1016\/j.tcm.2023.01.003_bib0041","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jacc.2017.11.014","article-title":"NHLBI Working Group Recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis","volume":"71","author":"Tsimikas","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.tcm.2023.01.003_bib0042","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/ajcn\/nqab287","article-title":"Effects of a low-carbohydrate diet on insulin-resistant dyslipoproteinemia-a randomized controlled feeding trial","volume":"115","author":"Ebbeling","year":"2022","journal-title":"Am J Clin Nutr"},{"issue":"12","key":"10.1016\/j.tcm.2023.01.003_bib0043","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa672","article-title":"Treatment of thyroid dysfunction and serum lipids: a systematic review and meta-analysis","volume":"105","author":"Kotwal","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.tcm.2023.01.003_bib0044","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/j.1463-1326.2005.00545.x","article-title":"Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women","volume":"8","author":"Salpeter","year":"2006","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.tcm.2023.01.003_bib0045","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1161\/01.ATV.20.4.1137","article-title":"Major reduction in plasma Lp(a) levels during sepsis and burns","volume":"20","author":"Mooser","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"7","key":"10.1016\/j.tcm.2023.01.003_bib0046","doi-asserted-by":"crossref","DOI":"10.3390\/nu12072024","article-title":"Diet and Lp(a): does dietary change modify residual cardiovascular risk conferred by Lp(a)?","volume":"12","author":"Enkhmaa","year":"2020","journal-title":"Nutrients"},{"issue":"5","key":"10.1016\/j.tcm.2023.01.003_bib0047","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/ki.1993.357","article-title":"Lipoprotein(a) in nephrotic syndrome","volume":"44","author":"Stenvinkel","year":"1993","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.tcm.2023.01.003_bib0048","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/0026-0495(86)90150-2","article-title":"Fluctuations of plasma lipoprotein-A concentrations during pregnancy and post partum","volume":"35","author":"Zechner","year":"1986","journal-title":"Metabolism"},{"issue":"23","key":"10.1016\/j.tcm.2023.01.003_bib0049","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.tcm.2023.01.003_bib0050","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1194\/jlr.P021113","article-title":"Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a)","volume":"53","author":"Deshmukh","year":"2012","journal-title":"J Lipid Res"},{"issue":"5","key":"10.1016\/j.tcm.2023.01.003_bib0051","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1399-0004.1997.tb04342.x","article-title":"Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study","volume":"52","author":"Berg","year":"1997","journal-title":"Clin Genet"},{"issue":"10155","key":"10.1016\/j.tcm.2023.01.003_bib0052","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S0140-6736(18)31652-0","article-title":"Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials","volume":"392","author":"Willeit","year":"2018","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.tcm.2023.01.003_bib0053","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1093\/eurheartj\/ehz310","article-title":"Statin therapy increases lipoprotein(a) levels","volume":"41","author":"Tsimikas","year":"2020","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.tcm.2023.01.003_bib0054","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk","volume":"139","author":"O'Donoghue","year":"2019","journal-title":"Circulation"},{"issue":"44","key":"10.1016\/j.tcm.2023.01.003_bib0055","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1093\/eurheartj\/ehaa649","article-title":"Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial","volume":"41","author":"Szarek","year":"2020","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.tcm.2023.01.003_bib0056","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","article-title":"Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome","volume":"75","author":"Bittner","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.tcm.2023.01.003_bib0057","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1194\/jlr.R056549","article-title":"Lipoprotein apheresis to treat elevated lipoprotein (a)","volume":"57","author":"Waldmann","year":"2016","journal-title":"J Lipid Res."},{"issue":"11","key":"10.1016\/j.tcm.2023.01.003_bib0058","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.metabol.2016.08.007","article-title":"Effect of extended-release niacin on plasma lipoprotein(a) levels: a systematic review and meta-analysis of randomized placebo-controlled trials","volume":"65","author":"Sahebkar","year":"2016","journal-title":"Metabolism"},{"issue":"24","key":"10.1016\/j.tcm.2023.01.003_bib0059","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Investigators","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.tcm.2023.01.003_bib0060","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"Group","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.tcm.2023.01.003_bib0061","doi-asserted-by":"crossref","first-page":"17887","DOI":"10.1038\/s41598-018-36204-7","article-title":"Impact of ezetimibe on plasma lipoprotein(a) concentrations as monotherapy or in combination with statins: a systematic review and meta-analysis of randomized controlled trials","volume":"8","author":"Sahebkar","year":"2018","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.tcm.2023.01.003_bib0062","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12916-017-0787-7","article-title":"Comparison of the effects of fibrates versus statins on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of head-to-head randomized controlled trials","volume":"15","author":"Sahebkar","year":"2017","journal-title":"BMC Med"},{"issue":"3","key":"10.1016\/j.tcm.2023.01.003_bib0063","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jacl.2015.03.003","article-title":"Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance","volume":"9","author":"Thompson","year":"2015","journal-title":"J Clin Lipidol"},{"issue":"11","key":"10.1016\/j.tcm.2023.01.003_bib0064","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0735-1097(20)32480-3","article-title":"6 monthly inclisiran and atherogenic lipoprotein reductions in Orion-11","volume":"75","author":"Kausik Kumar Ray","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.tcm.2023.01.003_bib0065","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.atherosclerosis.2008.07.019","article-title":"Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy","volume":"203","author":"Chasman","year":"2009","journal-title":"Atherosclerosis"},{"issue":"39","key":"10.1016\/j.tcm.2023.01.003_bib0066","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1093\/eurheartj\/ehac377","article-title":"Lipoprotein(a) is associated with the onset but not the progression of aortic valve calcification","volume":"43","author":"Kaiser","year":"2022","journal-title":"Eur Heart J"},{"issue":"7","key":"10.1016\/j.tcm.2023.01.003_bib0067","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1001\/jamacardio.2018.1470","article-title":"Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a mendelian randomization analysis","volume":"3","author":"Burgess","year":"2018","journal-title":"JAMA Cardiol"},{"issue":"6","key":"10.1016\/j.tcm.2023.01.003_bib0068","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1001\/jamacardio.2019.1041","article-title":"Estimation of the required lipoprotein(a)-lowering therapeutic effect size for reduction in coronary heart disease outcomes: a mendelian randomization analysis","volume":"4","author":"Lamina","year":"2019","journal-title":"JAMA Cardiol"},{"issue":"16","key":"10.1016\/j.tcm.2023.01.003_bib0069","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.tcm.2023.01.003_bib0070","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1089\/nat.2018.0736","article-title":"GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics","volume":"28","author":"Springer","year":"2018","journal-title":"Nucleic Acid Ther"},{"issue":"19","key":"10.1016\/j.tcm.2023.01.003_bib0071","doi-asserted-by":"crossref","first-page":"10969","DOI":"10.1093\/nar\/gkx818","article-title":"Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc-siRNA conjugates","volume":"45","author":"Nair","year":"2017","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"10.1016\/j.tcm.2023.01.003_bib0072","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.tcm.2023.01.003_bib0073","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41591-021-01634-w","article-title":"Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)","volume":"28","author":"Koren","year":"2022","journal-title":"Nat Med"},{"issue":"20","key":"10.1016\/j.tcm.2023.01.003_bib0074","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","article-title":"Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease","volume":"387","author":"O'Donoghue","year":"2022","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.tcm.2023.01.003_bib0075","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2022.5050","article-title":"Single ascending dose study of a short interfering RNA targeting lipoprotein(a) production in individuals with elevated plasma lipoprotein(a) levels","volume":"327","author":"Nissen","year":"2022","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.tcm.2023.01.003_bib0076","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Erqou","year":"2009","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.tcm.2023.01.003_bib0077","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jacc.2019.03.524","article-title":"Elevated lipoprotein(a) and risk of ischemic stroke","volume":"74","author":"Langsted","year":"2019","journal-title":"J Am Coll Cardiol"}],"container-title":["Trends in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1050173823000051?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1050173823000051?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,12]],"date-time":"2024-10-12T13:07:05Z","timestamp":1728738425000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1050173823000051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":77,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S1050173823000051"],"URL":"https:\/\/doi.org\/10.1016\/j.tcm.2023.01.003","relation":{},"ISSN":["1050-1738"],"issn-type":[{"value":"1050-1738","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lp(a) - an overlooked risk factor","name":"articletitle","label":"Article Title"},{"value":"Trends in Cardiovascular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tcm.2023.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}